Senior Director, US Provider Access Strategy & Marketing at Gilead Sciences

Santa Monica, California, United States

Gilead Sciences Logo
Not SpecifiedCompensation
Senior (5 to 8 years), Expert & Leadership (9+ years)Experience Level
Full TimeJob Type
UnknownVisa
Biotechnology, Pharmaceuticals, HealthcareIndustries

Requirements

  • Reports to the Head of US Market Access
  • Leads the US Access Strategy and Marketing Team
  • Chairs the ATC Network Optimization, Expansion and Onboarding Committee in partnership with EDs of Customer Engagement, US Medical Affairs, US Quality, US Strategic Account Management, and GACO
  • Key member of the US Market Access Leadership Team
  • Collaborates closely with internal and external stakeholders
  • Based in Santa Monica, CA headquarters

Responsibilities

  • Partner with US Market Access Leadership Team and cross-functional colleagues to develop the US Market Access strategy and tactical plan
  • Oversee development of strategies, tactics, and resources to enable ATC network expansion into community oncology settings aligned with national and local strategies
  • Oversee development of strategies, tactics, and resources to enable and optimize ATC onboarding and success, partnering with sales for smooth handoffs and customer experience
  • Develop and chair Kite's US ATC Network Optimization, Expansion and Onboarding Committee
  • Lead development and execution of payer strategy, including engagement with national and regional payers for access to cell therapy portfolio
  • Oversee payer marketing initiatives to align with market access strategy and communicate value propositions
  • Drive value marketing efforts, including creation and dissemination of value stories tailored to payers
  • Develop and maintain payer-facing tools and resources for reimbursement, coverage, and economic evaluations
  • Collaborate cross-functionally to integrate payer strategy and value messaging into launch readiness and commercial activities
  • Oversee development of provider-facing market access resources, including training materials and onboarding content
  • Lead development of scalable, future-focused initiatives to enhance provider and payer readiness, optimize CAR-T service line economics, and support portfolio sustainability across payers, health systems, IDNs, GPOs, and providers
  • Drive innovation in provider engagement

Skills

Market Access Strategy
Payer Strategy
Provider Access
Marketing
ATC Network Optimization
Onboarding
Community Enablement
Strategic Account Management
CAR-T Therapies
Cell Therapy Portfolio

Gilead Sciences

Develops and commercializes biopharmaceuticals

About Gilead Sciences

Gilead Sciences focuses on discovering, developing, and commercializing medicines for various medical conditions, including HIV/AIDS, liver diseases, cancer, inflammatory and respiratory diseases, and cardiovascular issues. The company conducts extensive research and development to create new therapies, which are then marketed to healthcare providers, hospitals, and pharmacies after receiving regulatory approval. Gilead differentiates itself from competitors through its strong commitment to R&D and strategic partnerships, such as with SAP Ariba, to enhance its operations and product offerings. The company's goal is to improve health equity and access to care globally, working with communities to ensure that its medicines reach those in need.

Foster City, CaliforniaHeadquarters
1987Year Founded
$15,873.6MTotal Funding
IPOCompany Stage
Biotechnology, HealthcareIndustries
10,001+Employees

Benefits

Paid family time off and paid parental time off
Generous 401(k) contribution matching
Comprehensive medical plans that cover both physical and mental healthcare
Global Wellbeing Reimbursement
Time Off
Global Volunteer Day
Giving Together Program
Employee Support Programs
Flexible Work Options

Risks

Increased competition in HIV treatment from ViiV Healthcare's expanding drug portfolio.
Regulatory scrutiny over drug pricing could impact Gilead's U.S. market operations.
Patent expirations, like Truvada's, lead to increased generic competition and revenue loss.

Differentiation

Gilead's lenacapavir is recognized as the 2024 Breakthrough of the Year for HIV care.
Partnerships with LEO Pharma and Tubulis enhance Gilead's focus on inflammatory and cancer therapies.
Gilead's commitment to health equity initiatives like COMPASS and HepConnect sets it apart.

Upsides

Gilead's strategic partnerships expand its reach in inflammatory and oncology drug markets.
Investment in digital health technologies enhances Gilead's R&D and patient engagement.
Focus on sustainability improves Gilead's operational efficiency and corporate reputation.

Land your dream remote job 3x faster with AI